research use only

Ixazomib Citrate (MLN9708) Analogue Proteasome inhibitor

Name: Ixazomib Citrate (MLN9708) Analogue
Brand: Selleck Chemicals
SKU: S2181
Availability: InStock
Rating: 5 (14 reviews)

Cat.No.S2181

Ixazomib Citrate (MLN9708) Analogue is the analogue of Ixazomib Citrate (MLN9708) from WO2016165677A1. Ixazomib Citrate (MLN9708) immediately hydrolyzed to Ixazomib (MLN2238), the biologically active form, on exposure to aqueous solutions or plasma. Ixazomib (MLN2238) inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50/K_i of 3.4 nM/0.93 nM in cell-free assays, less potent to β1 and little activity to β2. Ixazomib (MLN2238) induces autophagy. Phase 3.

Chemical Structure

Molecular Weight: 517.12

Jump to

Quality Control

Batch: Purity: 99.70%

99.70

Related Targets	HDAC Caspase Secretase MMP HCV Protease Cysteine Protease Tyrosinase HIV Protease DPP Serine Protease
Other Proteasome Inhibitors	MG132 Epoxomicin (BU-4061T) ONX-0914 (PR-957) Oprozomib Delanzomib VR23 PI-1840 Marizomib (Salinosporamide A) MG-115 KSQ-4279 (USP1-IN-1)

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (193.37 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	0.5% hydroxyethyl cellulose Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	10.000mg/ml (19.34mM)	Taking the 1 mL working solution as an example, take 10 mg of this product, add it to 1 ml of 0.5% hydroxyethyl cellulose clear solution, and mix evenly to form a uniform suspension. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	517.12	Formula	C₂₀H₂₃BCl₂N₂O₉	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	1201902-80-8	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	B1(OC(=O)CC(O1)(CC(=O)O)C(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	20S proteasome (Cell-free assay) 0.93 nM(Ki) 20S proteasome (Cell-free assay) 3.4 nM
References	[1] https://pubmed.ncbi.nlm.nih.gov/20160034/ [2] https://pubmed.ncbi.nlm.nih.gov/21724551/ [3] https://pubmed.ncbi.nlm.nih.gov/30601533/ [4] https://patents.google.com/patent/WO2016165677A1/en?oq=WO+2016165677

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04998786	ACTIVE_NOT_RECRUITING	Multiple Myeloma at First Relapse	Nantes University Hospital	2021-12-14	PHASE2
NCT04305691	RECRUITING	Kaposi Sarcoma; Skin	AIDS Malignancy Consortium	2023-11-07	PHASE2
NCT04847453	ACTIVE_NOT_RECRUITING	Recurrent AL Amyloidosis; Refractory AL Amyloidosis	National Cancer Institute (NCI)	2022-08-03	PHASE1
NCT06744894	NOT_YET_RECRUITING	Multiple Myeloma	Navy General Hospital, Beijing	2025-01-01	PHASE2
NCT03376672	ACTIVE_NOT_RECRUITING	Multiple Myeloma	Raija Silvennoinen	2018-05-31	PHASE2
NCT03763162	ACTIVE_NOT_RECRUITING	Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma	M.D. Anderson Cancer Center	2019-01-17	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):